{"title":"CAR-T细胞在皮肤病学中的作用机制及其在自身免疫性疾病中的应用","authors":"Osmara Morales-Hernández, Silvia Méndez-Flores","doi":"10.5281/zenodo.14617135","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chimeric Antigen Receptor T (CAR-T) cells have revolutionized the treatment of hematological malignancies and are expanding into autoimmune rheumatological diseases. In dermatology, they open a new therapeutic field for autoimmune disorders.</p><p><strong>Objective: </strong>To evaluate the mechanisms of action and therapeutic applications of CAR-T cells in autoimmune dermatological diseases, exploring the challenges and future perspectives for their clinical application.</p><p><strong>Material and methods: </strong>A thorough review was conducted in PubMed of preclinical and clinical studies on the application of CAR-T in dermatological diseases, selecting articles from the last 5 years with a focus on autoimmune diseases.</p><p><strong>Results: </strong>The potential of CAR-T cells in autoimmune dermatological diseases is highlighted, such as in pemphigus vulgaris, where CAR-T cells targeting pathogenic anti-Dsg3 B cells have shown efficacy. In cutaneous lupus erythematosus, CAR-T cells directed at CD19 have achieved significant clinical remissions. Additionally, applications in psoriasis and melanoma are explored, although efficacy is limited by adverse factors.</p><p><strong>Conclusions: </strong>CAR-T therapy represents a promising option for the management of refractory dermatological diseases, with favorable results in preclinical and clinical models. However, its clinical implementation faces challenges such as optimizing safety and reducing off-target effects. Future research should focus on next-generation CARs and clinical trials that validate their efficacy and safety profile in dermatology.</p>","PeriodicalId":94200,"journal":{"name":"Revista medica del Instituto Mexicano del Seguro Social","volume":"63 2","pages":"e6626"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12054643/pdf/","citationCount":"0","resultStr":"{\"title\":\"[CAR-T cells in Dermatology: Mechanisms of action and applications in autoimmune diseases].\",\"authors\":\"Osmara Morales-Hernández, Silvia Méndez-Flores\",\"doi\":\"10.5281/zenodo.14617135\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Chimeric Antigen Receptor T (CAR-T) cells have revolutionized the treatment of hematological malignancies and are expanding into autoimmune rheumatological diseases. In dermatology, they open a new therapeutic field for autoimmune disorders.</p><p><strong>Objective: </strong>To evaluate the mechanisms of action and therapeutic applications of CAR-T cells in autoimmune dermatological diseases, exploring the challenges and future perspectives for their clinical application.</p><p><strong>Material and methods: </strong>A thorough review was conducted in PubMed of preclinical and clinical studies on the application of CAR-T in dermatological diseases, selecting articles from the last 5 years with a focus on autoimmune diseases.</p><p><strong>Results: </strong>The potential of CAR-T cells in autoimmune dermatological diseases is highlighted, such as in pemphigus vulgaris, where CAR-T cells targeting pathogenic anti-Dsg3 B cells have shown efficacy. In cutaneous lupus erythematosus, CAR-T cells directed at CD19 have achieved significant clinical remissions. Additionally, applications in psoriasis and melanoma are explored, although efficacy is limited by adverse factors.</p><p><strong>Conclusions: </strong>CAR-T therapy represents a promising option for the management of refractory dermatological diseases, with favorable results in preclinical and clinical models. However, its clinical implementation faces challenges such as optimizing safety and reducing off-target effects. Future research should focus on next-generation CARs and clinical trials that validate their efficacy and safety profile in dermatology.</p>\",\"PeriodicalId\":94200,\"journal\":{\"name\":\"Revista medica del Instituto Mexicano del Seguro Social\",\"volume\":\"63 2\",\"pages\":\"e6626\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12054643/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista medica del Instituto Mexicano del Seguro Social\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5281/zenodo.14617135\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista medica del Instituto Mexicano del Seguro Social","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5281/zenodo.14617135","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
[CAR-T cells in Dermatology: Mechanisms of action and applications in autoimmune diseases].
Background: Chimeric Antigen Receptor T (CAR-T) cells have revolutionized the treatment of hematological malignancies and are expanding into autoimmune rheumatological diseases. In dermatology, they open a new therapeutic field for autoimmune disorders.
Objective: To evaluate the mechanisms of action and therapeutic applications of CAR-T cells in autoimmune dermatological diseases, exploring the challenges and future perspectives for their clinical application.
Material and methods: A thorough review was conducted in PubMed of preclinical and clinical studies on the application of CAR-T in dermatological diseases, selecting articles from the last 5 years with a focus on autoimmune diseases.
Results: The potential of CAR-T cells in autoimmune dermatological diseases is highlighted, such as in pemphigus vulgaris, where CAR-T cells targeting pathogenic anti-Dsg3 B cells have shown efficacy. In cutaneous lupus erythematosus, CAR-T cells directed at CD19 have achieved significant clinical remissions. Additionally, applications in psoriasis and melanoma are explored, although efficacy is limited by adverse factors.
Conclusions: CAR-T therapy represents a promising option for the management of refractory dermatological diseases, with favorable results in preclinical and clinical models. However, its clinical implementation faces challenges such as optimizing safety and reducing off-target effects. Future research should focus on next-generation CARs and clinical trials that validate their efficacy and safety profile in dermatology.